Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
Type:
Grant
Filed:
December 28, 2022
Date of Patent:
May 7, 2024
Assignee:
ARBOR BIOTECHNOLOGIES, INC.
Inventors:
David A. Scott, David R. Cheng, Winston X. Yan, Tia M. Ditommaso
Abstract: Engineered FnCas9 variants are provided that have an enhanced kinetic activity and a broader PAM recognition. The protein engineering methodology introduced specific mutations that stabilized interaction between Cas9 enzyme and target DNA. The enhanced kinetic activity increases NHEJ-mediated editing, owing to more efficient DSB generation potential than WT FnCas9, and the broadened PAM specificity increases the target range of FnCas9 variants. Thus, the scope and accessibility of CRISPR-Cas9 system targets are widened, along with generating robust and highly specific engineered FnCas9 variants.
Type:
Grant
Filed:
October 25, 2022
Date of Patent:
April 30, 2024
Assignee:
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
Abstract: The present disclosure relates to compositions of matter and assay methods used to detect one or more non-nucleic acid targets of interest in a sample. The compositions and methods provide signal boost upon detection of non-nucleic acid targets of interest in less than one minute and in some instances instantaneously at ambient temperatures down to 25° C. or less, allow for massive multiplexing, high accuracy, minimal non-specific signal generation, and are easily reprogrammable.
Type:
Grant
Filed:
October 5, 2023
Date of Patent:
April 23, 2024
Assignee:
VedaBio, Inc.
Inventors:
Swetha Murali, Anurup Ganguli, Ketki Sawant, Ravi Vijayendran
Abstract: Disclosed herein are methods, compositions, and kits for engineering proteins using error-prone orthogonal replication (epOrthoRep) and yeast surface display (YSD).
Type:
Grant
Filed:
December 9, 2021
Date of Patent:
April 2, 2024
Assignees:
The Regents of the University of California, President and Fellows of Harvard College
Inventors:
Chang C. Liu, Alon Wellner, Ziwei Zhong, Arjun Ravikumar, Andrew Kruse, Conor Thomas McMahon
Abstract: Provided herein are gene editing systems and/or compositions comprising RNA guides targeting LDHA for use in genetic editing of the LDHA gene. Also provide herein are methods of using the gene editing system for introducing edits to the LDHA gene and/or for treatment of primary hyperoxaluria (PH), and processes for characterizing the gene editing system.
Type:
Grant
Filed:
November 4, 2022
Date of Patent:
March 26, 2024
Assignee:
ARBOR BIOTECHNOLOGIES, INC.
Inventors:
Quinton Norman Wessells, Jeffrey Raymond Haswell, Tia Marie Ditommaso, Noah Michael Jakimo, Sejuti Sengupta
Abstract: The present disclosure provides a method for knocking out an N-myristoyltransferase (NMT) gene from Eimeria tenella, and belongs to the technical field of microorganisms. The method includes: mixing sporozoites of Eimeria tenella with a pCRISPR::EtNMT plasmid and a pEtNMT::DHFR plasmid, and subjecting a resulting mixture to electrotransformation to obtain NMT gene-knockout Eimeria tenella. The method provided by the present disclosure can successfully knock out the NMT gene from Eimeria tenella, which lays a foundation for studying the function of the Eimeria tenella gene and developing a vaccine therefor.
Type:
Grant
Filed:
December 23, 2020
Date of Patent:
January 9, 2024
Assignee:
LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
Abstract: This disclosure relates mRNA therapy for the treatment of ornithine transcarbamylase deficiency (OTCD). mRNAs for use in the invention, when administered in vivo, encode human ornithine transcarbamylase (OTC), isoforms thereof, functional fragments thereof, and fusion proteins comprising OTC. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of OTC expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic ammonia associated with deficient OTC activity in subjects.
Type:
Grant
Filed:
November 21, 2018
Date of Patent:
January 2, 2024
Assignee:
ModernaTX, Inc.
Inventors:
Zhijian Zhuo, Andrea Lea Frassetto, Paolo G. V. Martini, Vladimir Presnyak, Patrick Finn